Recently, the prognostic impact of NPM1 mutation MRD in AML patients receiving GO was determined in the phase III AMLSG 09-09 trial, that analyzed 7526 samples, including peripheral blood and bone marrow, from 469 patients [130]. Here, NPM1 is linked to acute myeloid leukemia.